Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure
Stephanus Malherbe and colleagues conducted positron emission tomography–computerized tomography lung scans of patients before and after tuberculosis therapy and report that even in cured, culture-negative patients the majority show lung lesions after 6 months of therapy, suggesting possible persist...
Gespeichert in:
Veröffentlicht in: | Nature medicine 2016-10, Vol.22 (10), p.1094-1100 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Stephanus Malherbe and colleagues conducted positron emission tomography–computerized tomography lung scans of patients before and after tuberculosis therapy and report that even in cured, culture-negative patients the majority show lung lesions after 6 months of therapy, suggesting possible persistence of
Mycobacterium tuberculosis
infection.
The absence of a gold standard to determine when antibiotics induce a sterilizing cure has confounded the development of new approaches to treat pulmonary tuberculosis (PTB). We detected positron emission tomography and computerized tomography (PET–CT) imaging response patterns consistent with active disease, along with the presence of
Mycobacterium tuberculosis
(MTB) mRNA in sputum and bronchoalveolar lavage samples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month treatment plus 1 year follow-up, including patients with a durable cure and others who later developed recurrent disease. The presence of MTB mRNA in the context of nonresolving and intensifying lesions on PET–CT images might indicate ongoing transcription, suggesting that even apparently curative treatment for PTB may not eradicate all of the MTB bacteria in most patients. This suggests an important complementary role for the immune response in maintaining a disease-free state. Sterilizing drugs or host-directed therapies, and better treatment response markers, are probably needed for the successful development of improved and shortened PTB-treatment strategies. |
---|---|
ISSN: | 1078-8956 1546-170X |
DOI: | 10.1038/nm.4177 |